Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement

Oslo, 4 August 2026: Reference is made to the resolution by the Annual General Meeting of Zelluna ASA (the "Company") held on 23 April 2026, authorising the Company's Board of Directors to increase the share capital by up to NOK 800,000 to settle amounts owed to Inven2 AS ("Inven2") under an option and license agreement with the Company's wholly owned subsidiary Zelluna Immunotherapy AS, upon dosing of the first patient in the first clinical trial for a licensed product. Reference is further made to the Company's stock exchange announcement made on 13 July 2026, confirming that such dosing has now taken place.